Pfizer's ELREXFIO™ receives U.S. FDA accelerated approval for relapsed or refractory multiple myeloma
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Aflibercept 8 mg first to achieve sustained vision gains with more than 70% of patients extended to intervals between 16 and 24 weeks in wet age-related macular degeneration at two years
- Details
- Category: Bayer
Bayer today announced two-year (96 weeks) topline results of the pivotal clinical trial PULSAR in patients with neovascular (wet) age-related macular degeneration (nAMD). The data reinforce sustained vision gains with unprecedented extended treatment intervals of aflibercept 8 mg reaching up to 24 weeks with efficacy and safety comparable to the current standard of care Eylea™ (aflibercept 2 mg) with fixed intervals of 8 weeks.
Bill & Melinda Gates Foundation, Children's Investment Fund Foundation, Pfizer and Becton, Dickinson & Company expand partnership for greater access to injectable contraceptive for women in low- and lower-middle-income countries
- Details
- Category: Pfizer
To help enable greater access to injectable contraceptives for millions of women in low- and lower-middle income countries, the Bill & Melinda Gates Foundation, Children's Investment Fund Foundation (CIFF), Pfizer and Becton, Dickinson & Company (BD) announced the expansion of their nearly decade-long collaboration. The expanded collaboration is expected to deliver more than 320 million doses of Pfizer's injectable contraceptive, Sayana® Press (medroxyprogesterone acetate)(1) administered by BD Uniject™ Auto-Disable Prefillable Injection System, through 2030.
New research published in Science highlights potential of a naturally occurring bacterium to help eradicate malaria
- Details
- Category: GlaxoSmithKline
Research published in Science today shows that a naturally occurring bacterium discovered by GSK scientists - Delftia tsuruhatensis Tres Cantos 1 (TC1) - could be the basis for new anti-malarial interventions. Studies done in collaboration at the Johns Hopkins Malaria Research Institute at Johns Hopkins Bloomberg School of Public Health show that the bacterium can significantly reduce the malaria parasite load in both the mosquito midgut and salivary glands indicating the potential of TC1 to inhibit transmission of the parasite to humans via the mosquito.
AI drives new era of target identification and drug design
- Details
- Category: Business
Disease modeling and target identification are critical and time-consuming portions of the drug discovery process and areas where artificial intelligence (AI) is already making a substantial impact. A new opinion paper in the Cell Press journal Trends in Pharmacological Sciences traces the history of target discovery methods - from experimental approaches, to
Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies
- Details
- Category: AstraZeneca
Alexion, AstraZeneca Rare Disease, announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer). The agreement furthers Alexion and AstraZeneca's commitment to advancing next-generation genomic medicines with the addition of complementary pipeline assets and innovative technologies.
Pfizer announces executive leadership to advance oncology research and development strategy
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology.
Effective today, Chris Boshoff, M.D., PhD, will join Pfizer's Executive Leadership Team as Chief Oncology Research and Development Officer and Executive Vice President reporting to
More Pharma News ...
- AbbVie and Calibr expand strategic collaboration to advance several preclinical and early-stage clinical assets
- Pfizer announces New England Journal of Medicine publication on Group B Streptococcus (GBS) maternal vaccine candidate
- Novartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma
- Flagship Pioneering and Pfizer partner to accelerate development of innovative medicines targeting unmet needs
- AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
- AbbVie secures positive CHMP opinion for atogepant for the preventive treatment of adults with migraine
- Bayer extends partnership with Peking University to foster pharmaceutical innovation in China